Published: 2021-12-24

Page: 691-695


Department of Pharmacology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry 605502 Affiliated to Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.


Department of Pharmacology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry 605502 Affiliated to Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.


Department of Pharmacology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry 605502 Affiliated to Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.

*Author to whom correspondence should be addressed.


Pharmacovigilance refers to research and practices relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related concern. A key concern with the sale of prohibited pharmaceuticals over the counter in India is that there aren't enough adverse drug response (ADR) statistics on these drugs. The gastrointestinal system was the site of the majority of suspected ADRs, with patients reporting epigastric pain, nausea, and loose stools, followed by dermatological symptoms such as rashes, pruritus, and so on. The respiratory, auditory, immune, and central nervous systems were also implicated. Every drug reaction was double-checked with the treating physician and the literature. Antibiotic fixed dose combinations and non- steroidal anti-inflammatory drug fixed dose combinations produced the most ADRs, followed by analgesics and antipyretics fixed dose combinations, fluoroquinolones, and antihypertensive fixed dose combinations.

Keywords: Pharmacovigilance, combination drugs, antihypertensives, adverse drug reaction

How to Cite



Download data is not yet available.


Zhang H, Saravanan KM, Yang Y, Hossain MT, Li J, Ren X, Pan Y, Wei Y. Deep learning based drug screening for novel coronavirus 2019-nCov. Interdisciplinary Sciences. 2020;12(1):368-376.

de Oliveira VM, Gubert-Matos VT, Tutes AA, Ferreira CM, Vasconcelos-Pereira EF, Toffoli- Kadri MC, Monreal MT. Challenges of Pharmacovigilance in Brazil. Global Journal of Health Science. 2021;13(2):1-12.

Patel R, Sachan AK, Chaohan S, Tiwari A, Giri T, Ansari AS, Yadav RK, Siddiqui EM, Pandey SK, Yadav BS, Chaudhary N. Present era of drug safety in India: An overview. Journal of Pharmacovigilance and Drug Research. 2021;2(1):1-8.

Sreedhar D, Subramanian G, Udupa N. Combination drugs: Are they rational. Current Science. 2006;91:406.

Foster S. Supply and use of essential drugs in sub-Saharan Africa: some issues and possible solutions. Social Science & Medicine. 1991;32(11):1201-1218.

Bharathkumar N, Sunil A, Meera P, Aksah S, Kannan M, Saravanan KM, Anand T. CRISPR/Cas-Based Modifications for Therapeutic Applications: A Review. Molecular Biotechnology. 2021;6:1-8.

Ambika S, Manojkumar Y, Arunachalam S, Gowdhami B, Sundaram KK, Solomon RV, Venuvanalingam P, Akbarsha MA, Sundararaman M. Biomolecular interaction, anti-cancer and anti-angiogenic properties of cobalt (III) Schiff base complexes. Scientific Reports. 2019;9(1):1-4.

Balaji RM, Chitra J, Sundaram KM. Studies on antidiabetic activity of indian medicinal plants using alpha-amylase and alpha-glucosidase inhibitory activity-A pathway to antidiabetic drugs. World Journal of Medical Sciences. 2015;12(3):207-212.

Gautam CS, Aditya S. Irrational drug combinations: Need to sensitize undergraduates. Indian Journal of Pharmacology. 2006;38(3):169.

Zhang H, Yang Y, Li J, Wang M, Saravanan KM, Wei J, Tze-Yang Ng J, Tofazzal Hossain M, Liu M, Zhang H, Ren X. A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro. PLoS Computational Biology. 2020;16(12): e1008489.

Viswanathan A, Kute D, Musa A, Mani SK, Sipilä V, Emmert-Streib F, Zubkov FI, Gurbanov AV, Yli-Harja O, Kandhavelu M. 2- (2-(2, 4-dioxopentan-3-ylidene) hydrazineyl) benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma. European Journal of Medicinal Chemistry. 2019;166:291- 303.

Cardwell K, Kerse N, Ryan C, Teh R, Moyes SA, Menzies O, Rolleston A, Broad J, Hughes CM. The Association between Drug Burden Index (DBI) and health-related outcomes: A longitudinal study of the ‘oldest old’(LiLACS NZ). Drugs & Aging. 2020; 37(3):205-213.

Sarma P, Kumar H, Medhi B. Cosmetovigilance in India: Need of the day. Indian Journal of Pharmacology. 2017; 49(5):341.

Lihite RJ, Lahkar M. An update on the pharmacovigilance programme of India. Frontiers in Pharmacology. 2015;6:194.

Zhang H, Li J, Saravanan KM, Wu H, Wang Z, Wu D, Wei Y, Lu Z, Chen YH, Wan X, Pan Y. An Integrated Deep Learning and Molecular Dynamics Simulation-Based Screening Pipeline Identifies Inhibitors of a New Cancer Drug Target TIPE2. Frontiers in Pharmacology. 2021;12:772296.

Srimathi Devi J, Haripriya D, Arul S, Saravanan KM, Bupesh G. Evaluation of anti- cancer effect of zerumbone and cisplatin on N- nitrosodiethylamine induced hepatic cancer in freshwater fish (Danio rerio). Natural Product Research. 2021;30:1-5.

Wightman KJ. Adverse reactions to antimicrobial therapy. Canadian Medical Association Journal. 1965;93(16):870.

Narmada S, Gowrav MP, Akki A, Motupalli V, Balamuralidhara V, Venkatesh MP. Global Perspective of Paediatric Pharmacovigilance and its Importance: Where Have We Reached?, Journal of Pharmaceutical Research International. 2021;33(46A):276- 288. DOI: 10.9734/jpri/2021/v33i46A32867

Eyer CL. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. American Journal of Pharmaceutical Education. 2002;66(1):95.

Comfort S, Perera S, Hudson Z, Dorrell D, Meireis S, Nagarajan M, Ramakrishnan C, Fine

J. Sorting through the safety data haystack: Using machine learning to identify individual case safety reports in social-digital media. Drug Safety. 2018;41(6):579-590.

Saravanan KM, Zhang H, Zhang H, Xi W, Wei

Y. On the conformational dynamics of β- amyloid forming peptides: A computational perspective. Frontiers in Bioengineering and Biotechnology. 2020;8:532.